pH-Responsive and Actively Targeted Metal–Organic Framework Structures for Multimodal Antitumor Therapy and Inhibition of Tumor Invasion and Metastasis
Source abstract
Abstract
Multimodal treatment is an important tool to overcome tumor drug resistance. The reactive oxygen species (ROS) generated by photodynamic therapy (PDT) can directly play a killing role on tumor cells, which has the advantages of repeatable treatment and no drug resistance. However, its therapeutic oxygen consumption and destruction of tumor microvessels lead to hypoxia in tumor tissues, and hypoxia leads to overexpression of the receptor tyrosine kinase (c-MET) and vascular endothelial growth factor receptor (VEGFR). Overexpression of these two receptors leads to increased tumor invasiveness and metastasis. The molecularly targeted drug cabozantinib (CAB) has multiple targets, including anti-c-MET and VEGFR, to inhibit the development of hepatocellular carcinoma (HCC). In this study, our team designed a pH-sensitive nanoparticle CAB/Ce6@ZIF-8@PEG-FA (CCZP) loaded with CAB and Ce6, which exerted a multimodal therapeutic effect of PDT and molecularly targeted therapy by laser irradiation, and the PDT-induced overexpression of MET and VEGFR could also be inhibited by the target of CAB, thus reducing the invasive tumor cells metastasis. In summary, CCZP gives full play to the advantages of both drugs, exerting multimodal treatment while reducing HCC invasion and metastasis, providing a safe, potential approach to clinical treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Medical School, Southeast University, Nanjing 210009, China
Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250000, China
Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China
Funding
Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Jiangsu Provincial Key Research and Development Program
References (47)
Show source-provided references
1. 10.1056/NEJMra171326310.1056/NEJMra1713263 ↗
2. 10.1053/j.gastro.2021.12.27610.1053/j.gastro.2021.12.276 ↗
3. 10.1038/nrclinonc.2017.16610.1038/nrclinonc.2017.166 ↗
4. 10.1038/nrc336610.1038/nrc3366 ↗
5. 10.1039/D0CS01370F10.1039/D0CS01370F ↗
6. 10.1038/nrc107010.1038/nrc1070 ↗
7. 10.1039/C6CS00271D10.1039/C6CS00271D ↗
8. 10.1039/C2CS35216H10.1039/C2CS35216H ↗
9. 10.1039/c3cs35531d10.1039/c3cs35531d ↗
10. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
11. 10.3322/caac.2011410.3322/caac.20114 ↗
12. 10.1016/j.biomaterials.2018.09.03310.1016/j.biomaterials.2018.09.033 ↗
13. 10.1016/S1535-6108(03)00085-010.1016/S1535-6108(03)00085-0 ↗
14. 10.1038/s41571-020-0377-z10.1038/s41571-020-0377-z ↗
15. 10.1038/sj.onc.120940910.1038/sj.onc.1209409 ↗
16. 10.1016/j.jhep.2013.09.00910.1016/j.jhep.2013.09.009 ↗
17. 10.1016/j.jhep.2016.05.00710.1016/j.jhep.2016.05.007 ↗
18. 10.1158/0008-5472.CAN-06-060410.1158/0008-5472.CAN-06-0604 ↗
19. 10.1038/nrm191110.1038/nrm1911 ↗
20. 10.1016/j.ccr.2009.01.02710.1016/j.ccr.2009.01.027 ↗
21. 10.1158/2159-8290.CD-11-024010.1158/2159-8290.CD-11-0240 ↗
22. 10.3322/caac.2141110.3322/caac.21411 ↗
23. 10.1038/s41392-020-00264-x10.1038/s41392-020-00264-x ↗
24. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
25. 10.1111/liv.1510110.1111/liv.15101 ↗
26. 10.1056/NEJMoa070885710.1056/NEJMoa0708857 ↗
27. 10.1158/1078-0432.CCR-13-262010.1158/1078-0432.CCR-13-2620 ↗
28. 10.1016/j.ctrv.2021.10222110.1016/j.ctrv.2021.102221 ↗
29. 10.1056/NEJMoa171700210.1056/NEJMoa1717002 ↗
30. 10.1093/annonc/mdw65110.1093/annonc/mdw651 ↗
31. 10.1159/00051986710.1159/000519867 ↗
32. 10.1007/s11523-020-00736-810.1007/s11523-020-00736-8 ↗
33. 10.1056/NEJMoa202698210.1056/NEJMoa2026982 ↗
34. 10.1016/j.apsb.2022.03.01010.1016/j.apsb.2022.03.010 ↗
35. 10.1002/adma.20200186210.1002/adma.202001862 ↗
36. 10.1002/adma.20170419610.1002/adma.201704196 ↗
37. 10.1016/j.cclet.2021.09.08410.1016/j.cclet.2021.09.084 ↗
38. 10.1002/adma.20180020210.1002/adma.201800202 ↗
39. 10.1002/adma.20220087110.1002/adma.202200871 ↗
40. 10.1039/C9TB02482D10.1039/C9TB02482D ↗
41. 10.1021/acsnano.2c0551710.1021/acsnano.2c05517 ↗
42. 10.1016/j.colsurfb.2020.11089110.1016/j.colsurfb.2020.110891 ↗
43. 10.1016/j.biomaterials.2020.11976110.1016/j.biomaterials.2020.119761 ↗
44. 10.3390/antiox1009133610.3390/antiox10091336 ↗
45. 10.1038/s41419-022-05022-110.1038/s41419-022-05022-1 ↗
46. 10.1038/s41568-020-00307-z10.1038/s41568-020-00307-z ↗
47. 10.1016/j.stem.2010.11.02810.1016/j.stem.2010.11.028 ↗